Your email has been successfully added to our mailing list.

×
-0.000735023888276353 -4.59389930172313E-05 -0.000137816979051824 -0.00174660051451673 -0.00248070562293271 -0.00422638735758919 -0.0105200294009555 -0.00739617787578103
Stock impact report

Alexion's stock is up after announcing trial for COVID-19 patients [MarketWatch]

Alexion Pharmaceuticals, Inc (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
Company Research Source: MarketWatch
Shares of Alexion Pharmaceuticals Inc. gained 2.1% in trading on Monday morning after the drugmaker announced it plans to conduct a Phase 3 trial testing Ultomiris in patients with severe forms of COVID-19. The open-label, randomized, controlled clinical study aims to enroll 270 patients hospitalized with severe pneumonia or acute respiratory distress syndrome in May. The drug has previously been approved by the Food and Drug Administration to treat two rare diseases. Alexion's stock is down 3.4% year-to-date, while the S&P 500 has dropped 11.0%. Show less Read more
Impact Snapshot
Event Time:
ALXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALXN alerts
Opt-in for
ALXN alerts

from News Quantified
Opt-in for
ALXN alerts

from News Quantified